Provention Bio (PRVB) 3 Nov 222022 Q3 Earnings call transcript

Good morning. My name is Brandon, and I will be your conference operator for today. At this time, I would like to welcome everybody to the Provention Bio Third Quarter 2022 Financial Results Conference Call. [Operator Instructions]

I would now like to turn the conference over to Heidy King-Jones, Chief Legal Officer of Provention Bio. ahead. go Please

and operator, all joining for Thank thank us. you, you

interactions Executive Ashleigh on of regulatory Officer Prevention Chief our corporate Bio quarter update Co-Founder an and Palmer, progress. provide will third and first

a Chauche, the update will as who highlight of anticipation our as with Officer, summary of co-promotion turning Chief preparations commercial then potential activity. Thierry of will call Hoitt, as agreement the Jason well Before quarter our on our to third launch Officer, Commercial strategic financial teplizumab’s our provide financing status our Chief Financial in over our as Sanofi. well results an

candidates, product plans use runway; and other Before for safety, same. and towards and review entered constitute and the our the Sanofi connection with an FDA regulatory we various efforts today continuing timing at-risk our forward-looking the product our other the commercialization teplizumab statements developments that the agreements projections, clinical these approval and our prospects expectations to in and teplizumab, a we about to the me begin, our time plans plans and remind commercialization continue teplizumab include including candidates, our anticipated business and financial potential you cash future of our resubmission study FDA make lines with remarks of indication, potential of and related they we our cash for success results, will for and BLA commercial statements and and as securing of efficacy let including into with potential projected working our

filings a today Risk those including Any we important report may with future. of of from most Factors SEC those as Form recently in may as the make discussed differ Actual indicated our various by other views only. the the and materially factors, XX-Q statements forward-looking on in our forward-looking that quarterly section represent in of results result statements

regarding our statements forward-looking forward-looking by the Therefore, representing update disclaim our as as to as to we elect specifically obligation may at and Investors is and change, these these of any more any you you rely prevention section. future, if in required documents information some encourage reports we on statements While date uncertainties views even except today. statements, point with not these the These risks to so we should views law. do There We complete www.proventionbio.com are at Provention’s documents carefully. on forward-looking the under file subsequent to review SEC. website available

call over With that, I to now turn the Ashleigh. will

morning, BLA or diabetes to of of everyone. our breakthrough the Throughout third the Stage in you, resubmitted individuals. therapy-designated or FDA TXD III has the Stage for and good X team Thank at-risk continued clinical type delay support quarter, Heidy, interact teplizumab with our in X

post-marketing received June, have pleased requirements notice, amendment requirements expectations with during proposed the generally consistent FDA and market the FDA’s review and am that we XXXX. major XX, proposed planned informed end post-marketing report and date. the I commitments the labeling to and the are we FDA’s In were us identified public since to these guidance commitments that no if of the to its at proposed received October labeling major communicate by and agency deficiencies that and both our

Our encouraging. is labeling receipt and proposed timely the commitments of requirements post-marketing and FDA’s

Sanofi, and dependency. the onset ongoing Under approved, at-risk commercialization of to our potential individuals disease in of the III with interactions, distribution insulin we continues including TXD its for first with application. Sanofi, to all and our always over to for potential to make therapy the co-promotion the Nevertheless, clinical and teplizumab, decision packaging, if for is aspects commercial change Stage as the a become, parallel preparing possibility caution that with X strategy with the yet review negotiations, there In have regulatory maintain also soon our FDA circumstances of collaborating U.S. pricing. BLA, the agreement we final must regarding disease-modifying launch been prevention agency our delay can closely FDA continues might has stage what control ever of labeling partner,

call further handing to of the Before potential over our launch and approval. anticipation to teplizumab’s preparations Jason planning discuss in

TXD includes throughout our our continued IIb has II our IIa Phase Let partnership evaluating PREVAIL progress monoclonal autoimmune Phase with me development all trial disease programs. the team III erythematosus. also mention lupus trial, ordesekimab focused new nonresponsive PROTECT in evaluating celiac across make Amgen, teplizumab steady onset This that antibody our disease. evaluating anti-IL-XX proactive quarter, systemic our our And to Phase trial, clinical PRV-XXXX for for third for

also partners stages with in next development our of candidate, polyvalent prospective for B are regarding We coxsackievirus discussions the PRV-XXX. vaccine

I Jason. that, to With like over would to hand

believe teplizumab in We the FDA for TXD individuals. at Ashleigh team is decision commercialization approval regarding you, X Stage Thank Bio a potential well at risk Prevention prepared

will Navigator Compass the start to approval. coverage market be team months. on will for which take teplizumab, forms in on and to access expect processing payers following with medical of X field support getting will Our our we work team developed receiving enrollment X day parallel, In ready policies

co-pay insurance patients working medical In through launch, in days to assistance the eligible insured get helping commercially program. early our and enrolled compliantly exception for of coverage the anticipate we process

education We a requests on soon will than major field physicians care have start members to specialists in at be team of from educating as more part initiated our pilot sales ago. and health to approval excellence after year the board centers of therapeutic These providers. unsolicited X a for team responding

launch previous we over with review. in we notice readiness were mentioned summer when received FDA to I’ve of the excellent in delay respect calls, the shape As on

November work reinitiated fully date. track key action are core are Educational have and and We hiring readiness launch activities related on for distribution all our contracting materials, partners, with communication to streams prepared XX. FDA for

them and the by planned of during FDA approval. have month force, upon We’re accepted pleased the contingent to our of December, onboard offers conditional majority been sales to announce to plan that us join we

from and our we’re on been leadership that of forces the October medical affairs to Sanofi terms Since go X, the commercial ready with the have teplizumab, announcement combining teams under Sanofi agreement. meeting co-promotion if co-promote and ensure we’re to Provention core that to approved,

This for we planned about headcount recruitment our the on We part some weeks commercial our ramp-up. nicely the and deploy next will few Sanofi in sets stage from progress and the the additional remain both be colleagues early of doing remaining to this over additional to of the and launch teplizumab, track for be initial field-based Sanofi our positions during team January. continue from excited new

be prevention team Sanofi of and December into in programs and the training in expect full We with field teams conducting deployment the joint January. will the entire

to attend palpable to International and mentioning it’s care the for say whom conference Pediatric few Finally, Society interacted was the meeting. of Provention. the a potential a with had And we that worth there among a I Adolescent from at the colleagues providers chance ago, weeks excitement have health diabetes I few teplizumab alongside of about many

potential important with over the FDA ran the standing approval. new of look at We symposium and our others bring market, Our this with working minutes Congress to to organizations and forward audience. was patients, receipt treatment to time advocacy pending physicians, closely room nearly from questions only XX

to turn over now call to financials. to I’d like Thierry? the our Thierry discuss

Jason. you, Thank

press The read earnings your as to XX-Q our quarter and includes encourage you statements, attention the that to discussing I condition. call today. our begin to I risk our management’s would as call. the analysis I would financials, XX-Q prior also filed to discussion release, third of well was was issued Before financial factors this financial which like

the with $XX $X.XX basic million loss for share $XX.X share diluted generated the and or P&L. start We quarter of diluted to a compared quarter net loss XXXX $X.XX per per of the XXXX. third for third me Let of million a of net or basic and

the XXXX $XX.X period PROTECT the Our third as driven for in in XXXX decrease R&D trial by in for the to million in enrollment increase for enrollment XXXX. our associated an during were the including cost trial activities. of for August expenses This pre-commercial to was teplizumab million driven target compared was XXXX. costs the XXXX, decrease period program, during $XX.X and was same of the study with were partially third expenses G&A compared ordesekimab offset million by by million $XX PRV-XXXX. IIa PREVAIL reached of same year-over-year increased $XX.X the of quarter The lower for proactive quarter

by noncash depreciation guidance number and of revenue came which XXXX cash-based cash During This were expense stock-based below our third end Huadong, of collaboration and quarter million, of the our quarter, for $X.X lower $X.X we recognized expenses million under of management. approach to cautious slightly million. driven the compensation million $X.X of with $XX.X our agreement first the operating excludes expenses also license our

now cash and Turning to current projection. our cash position

was third our private and As facility position at-the-market our includes million completed our from million. raised $XXX.X of cash, during of first This proceeds loan with our of net marketable cash quarter through September as the XXXX, tranche million as million XX, Hercules of $XX.X term $XX.X equivalent $XX.X securities well from July, the in placement XXXX. program the

continue globally over have opportunistic research, use $XXX million on we Sanofi, our under commercialize $XX negotiation with develop, in first from of currently to to exercisable nonrefundable We Sanofi our through XXXX of the program. right of and the just regarding be co-promotion agreement this the million October, TXD. we available payment In teplizumab for received program, and June at-the-market will manufacture capacity

is discretion, figure our of September to in will million If volume-weighted quarter $XX at teplizumab will but date our the purchase purchase This included in closing million price at XX% the the securities to average FDA approved financial agreement, being date, closing be cited no XX, under is XX stock for XXXX. this the Sanofi $XX with as later prior the X-day premium by prevention fourth and February payment a than not common reflected results. cash

term ability will million. the next we loan $XX under addition, facility, In tranche have totaling our to the draw

believe payments. that of a commercial from to provides with Based if approved, that estimated changed to our is milestone contingent cash marketable launch our launch cost we through this securities and commercial business equivalents XXXX. a Sanofi capital us guidance changes Hercules on our runway with of and co-promotion could level including together be that on note us and commitments potential hand, agreement our teplizumab and approval plan, the current cash, Sanofi commercialization, on success current cash potential the of support Please under successful enables of by

in gated approval expect the be between million $XX teplizumab, potential of scenario assuming potential launch We and and quarter in prudent well FDA XXXX, preparation expenses as the operating we and commercial million in our towards work as we be continue spending of to $XX and cash-based teplizumab the to our approval in where fourth spend the In PRVXXX an as ordesekimab approval reflecting a for of for in our diagnosed program data runway in increase our which of III November. teplizumab disease November, celiac TXD, which not we is estimate XXXX. currently top obtained the our readout study from expected that is FDA IIb newly Phase the as through the PROTECT beyond of XXXX as from after trial nonresponsive half well XXXX, in proactive the is extend line at cash end will Phase completion in of expected the second for

As of receive to Provention within with Amgen the to to $XXX a elect trial after delivery final eligible overall the exercise should milestone to proactive control respect ordesekimab. assume a package data from XXX days for activity million the right payment reminder, is its Amgen

us approval potential our provides of when Finally, most strategic as and evidenced of by optionality momentum we be activities, teplizumab financing to with continue recent in both take to we believe FDA transactions. will evaluating November our opportunistic and capital, potential care a additional with

the With Ashleigh. that call update, over now turn I will to

Thierry. you, Thank

systems for life-threatening and strategic our near in a mission We on disruptive health platform at-risk corporate and autoimmune X becomes the care remains with the firmly teplizumab and and stage Stage clinical shift serious TXD. of Our industry in diseases. debilitating the of individuals intent focused future hope conceptual this paradigm with approval programs reality our catalyzing a how manage potential

teplizumab their hard quickly the In the and therapy would disease to patients, closing, hope all late to clinicians Provention community bring FDA the decision families, what we in would then plan thank to a as receive to to process. stage precious to caregivers Stage We ever therapy work at-risk be this like a the review breakthrough effectively the approved, designated team X bring serve. coming the weeks I agency’s and positive for and TXD modifying if the and first and in

questions. we open call that, With operator, like would to the for

[Operator Oppenheimer. Instructions] Kim Our comes first from question Justin with

the pricing pricing? or filing. of of proposed changes expected company potential post-marketing of the with of in any have associated terms considerations the payers about Great been wondering, with thinking just any to has teplizumab you you’ve But for hear And do updates conducted how to that conducted labeling sort launch? discussions the you sort with and the any have

you thank question. the Justin, for

that a received result taking at hand Jason, full who Jason? of of of as review has I’ll advantage time to amendment the So over end we the been additional June. the

Yes.

We’ve we’re Justin, on thanks for mentioned change the no I’ve as completed, pricing our question. previously concerned. calls, far Really research. as as

yet We haven’t set until potential and time announcing label our the a locked, we that approval. final we at that would intend final of price don’t and have to final price anticipate

which with been the label, consistent. streamlined from to achieve. mentioned really been Payers precisely I’ve we’ve though, before, strategy they covering hoping off years us teplizumab the prior has X payers over hearing is to told we’re As X feedback have the that a last nearly anticipate

of maybe with talked past the a I’m Okay. teplizumab on commitments. speak sort or PROTECT. the upon even more even approval? Great. the we’ve aside sort the is just broaden Great. potential to studies wondering, that setting post-marketing team the discussions to there to studies specific sort of beyond know maybe of excited use of about are And in additional initiate just FDA I sort of

Yes. you, Justin. Thank

we patients age enough focus below population. to fortunate the yes, to labeling approval we’re if So get X on of into to years excited younger expand are

therapy, a excited the about therapies, additional therapy teplizumab BX We’re course the of redosing prospect excited studies from cellular prospect seen to additional extend whether about courses of cell of we’re single the co-administration of determine delay dosing transplantation. with could of

celiac who autoantibodies. potential type diseases, teplizumab other targeting And just autoimmune diabetes at-risk We’re excited teplizumab’s of evaluating prospect of that, X such excited have to Stage patients, outside about beyond than earlier the cell-mediated on disease. stage explore as at T X we’re X individuals X Stage

Your with from comes next Howerton question Chris Jefferies.

label. very excited that to I’m hear the you proposed have

those have guess first, that that requirements, for That’s be post-marketing questions So what to us could I be, additional color with any might that X any question could work the expecting? the one. I you’re me you clinical give respect required on is,

expires, could just with if And of be of factor both two, the terms period, me, we so myself I’ve we’ve when first negotiation some I into had in potentially the when the then confusion, great. of question might think, might data PROTECT that and and right the PROTECT investors how get of with kind requires excuse data that period you clarify would

Thanks, Chris.

we So regarding the PMCs with received consistent they and guidance PMRs, to markets. prior as I said in them, public our my have script, are and

any mind post statement, time. as change marketing And agency are I of our historically as opening proposed set to patients safety the that. to think a commitments, But been clarify, the that X and with study at years can evaluate final, safety. to in has its requirements the long-term So study pediatric to in a conduct public market age as up under PK/PD and also it’s post-marketing consistent mentioned not registry I well guidance

study of guidance the the been first results available our right half has and of in from anticipate the line we year. that the Regarding next the second top study PROTECT negotiation, PROTECT being

top and that based have expires additional that payment, stated of in year. can end PROTECT. negotiation of coincide the on also We the of right potentially right negotiation announced line that June But of evaluating the first extend we’ve an of with that first Sanofi next could results

Got it.

that, I the just encompass that which to have that line results? you’re Ashleigh I correct? that extend So would the an negotiation and period, then Sanofi to that top Do could make additional anticipating they essentially, clarify, appreciate is payment

correct. That’s

Again, congratulations.

Thank Chris. you,

H.C. Wainwright. comes from Ram question next Selvaraju with Your

updates teplizumab. the if to label? allocated in see specific specific comment wondering could just how could for the or you there of a the out planned you been activities of a has sense bit Provention Sanofi was on in little us of any marketing I give revisions if the being preparation you this and across and And also context whether launch

much for question, very the Ram. Thanks

Jason? who over and with very hand Jason, has preparation I been Sanofi in So hard planning. in to colleagues working our

Ram. for question, Thanks the Yes.

as reach more centers health and to approval of excellence seeking infusing we educating have for respect responding acquiring to information potential therapeutic marketing the with I our start on prepared in been of the care a in field year to anticipate deploying shortly efficacy specific reactively how out and safety to X So providers that specialists now, a after mentioned and who over the about remarks, activities, go teplizumab. just teplizumab and

I have the early colleagues the teams in both progressing will anticipated As mentioned, in that part of the December training January. terms things in that of Sanofi the incredibly well of start deployment at deployment, new our joint joint early with been with

Now the we of when number they’re account disproportionately the co-promotion be of the while segment as said, Sanofi, focuses of market. pediatric directors dedicated market, adult that we with that the announced will endocrinology mentioned a with being disproportionately segment on deploying agreement the RTM on endocrinology focusing

potential teams. to approach it deployment FDA, from of Sanofi. some have being accelerate will joint raise that through in colleagues our awareness. early seen some excellent I accounts we’re redundancy around the Sanofi, of that with approval feel with Now should said, now with the able the that centers be middle some be of of complex in nearly the only we at that that level labeling the to the presence And that there awareness institutions X the with would January taking really that part new really level doubling to draft we field a of say validates we of academic and

hope labeling the changes Ram. discussions a answers activities deployment no to are our of that anticipated marketing question, I ongoing. your So as that result or

Yes, very much.

updated the wondering the you asset most overall I in appropriately. availability or beneficial of that this thoughts any strategic it think outcome drug ultimately, asset the be regarding position as to what candidate. the context strategic favorable So with commercial was teplizumab? XXX just to if you of the positioning quickly had you of And look on very most would respect

Ram. very Thanks much

a advanced that. commercialization feel we So stages do franchise, and best that that to able by party of the advanced be a of that, is development the asset has we’ll vaccine and

new diabetes is So for a We of we’re future. onset asset the to PRV-XXX there anticipate type medium-term and of partner. risk profile X that actively seeking positioning teplizumab the really near don’t any or conflict between that in the at

from SVB Your next with Securities. question Smith Thomas comes

the just of proposed remind us Maybe the It Actually, anything perspective gaining from around there’s whether CMC requirements. outstanding the the things side? on Congrats ongoing progress. the can just sounds review. you on on sort starting all like and BLA or appreciate nicely I manufacturing post-marketing there. comments really progressing the your labeling are you’re

Tom, that we will on resubmitted in the manufacturing in based favorable a and indicated, There had, agency’s the decision prior to the Yes, of related can at thank the questions event and date. regards and the be by we outstanding the anticipate original as addressed you. BLA, post-marketing in the we’ve agency. process on believe decision we advancing which of were manufacturing agency requirements that there prospect had so PDUFA assays and commitments the back

engagement? your that talk Don’t you, place of to and wondering you payer here. and streamline launch recent could sounds it follow And you time like just in if, could goals policies Jason, Jason? the up front the was Okay. just you’re It Got agreements access some of expecting Is already possible maybe take implement. commercial value-based of the at of want it. then some reimbursement? to could the time I if could some of to have the market on some sort payer tone

given market, contracting. said for the Thanks this question, Tom. anticipate we’ve that What we previously don’t is commercial Yes.

medical it’s the So across any time going to with payer time a launching audience. those we’re to take implement benefit, policies medical

that so putting closely to across our working policies directors and medical of they’re are market payers place to board very And directors to in access the teplizumab. going support reimbursement medical ensure be with

work through not those are that initially mean they’ll most, that policies sounds don’t hurdle, in being necessity exception is quick write of It through while requires can It not but little covered exception means Now a this by are patients it’s the the and be access. those products medical like policy. of place. letter that big relatively a but And medical medical the working until if just policy all and medical behalf be oftentimes, of just go physician bit benefit time, many, have a that patient early drafted, a on put it days. doesn’t to easy, in more

months I answers right be be generally, X some to for But is to in your hope policies time officially X side. about the frame put Tom. that’s quicker. general place that question, the on can payer guidance,

us give that’s status you Got super it. like maybe you Europe MHRA or teplizumab forward that the just an and with the path think kind in of what update might Yes, then just if region? of Okay. look helpful. on discussions in And and us Lastly, could remind the the

Tom. Thanks, Yes.

months advised U.K. the So States. in the approximately in in is an so or and past generally, Europe XX United here we’ve the approval that submission behind the

our So getting with through our FDA, final and is stages of partner, right focus now, approved by review teplizumab co-promotion Sanofi. effectively hopefully launched the the on

teplizumab global first us for And type on secured a of the X to right have is with Sanofi basis. respect which of with diabetes course, negotiation,

commercialization And Sanofi be successful, negotiation of bringing that play a negotiations a with would a like so we development. market to under regulatory very discussions anticipate submissions Sanofi that and and first right partner respect potential with significant these into international are ongoing

the progress. on Congrats

Your Jones next Trading. Agrawal Prakhar question comes from with

line congrats. Prakhar road getting so Ashleigh It’s is the that you for the but label, you’re the close regulatory front, long on to This Congratulations on and a from it been proposed finish seems team. Cantor.

my had expectations also with quick stage, is, the you base are case around the And on remind a could FDA? of kind points any of this expect the label. What I you at if us do And negotiation follow-up. box? key So question first the black

historic label mentioned from guidance the on. of with criteria we’ve FDA historic materially Again, proposed provided patient. you the study that the consistent in is that very guidance enrollment reminder Prakhar that X much, I X a so is autoantibodies and patients the with follow dysglycemia Stage will opening TNXX defining generally TXD that autoantibodies label remarks, a the as Thank the

are constrain of of agency does prided to the we’ve use patients years not diabetes. that familial X Patients X the relatives And in with who type teplizumab the hope over only age. past with we existing

opening And remarks that proposed with that is guidance. that. so the since to label regarding with guidance be the my has respect been an indicated expectation consistent historic not then would with historic And also a consistent black box,

on also, this important And readout secondly, Okay. us they remind Phase deal? trial, the if likely And global for III you out-licensing on could the how PROTECT is as trial decision make partners regulatory will well? from the endpoints be most as important? and If to endpoint hit a secondary is have many yes, Congratulations. primary standpoint, you the enough or on ones which how hitting

Thank you, Prakhar.

first Sanofi, earlier, study is into results mentioned of with when line of but prospect respect next right the there top negotiation to with as year the of in the Sanofi second partnership the of guided June PROTECT extending expires be of XXXX we’ve that So will the right negotiation available. assess that half

securing the with on patients FDA of teplizumab terms as we’ll successful assuming and have we primary at-risk secondary In approval closer the the of and to study top our in the focus the then and line market endpoint, discussions been of for PROTECT get onset the versus new that endpoint patients. study readout we update results that

with David question next Hoang SMBC. from comes Your

here to see be the to the and close teplizumab great progress. Congrats date. the Really on finish looking PDUFA all forward to line

So I just questions. of a had couple

types you terms you bit launch for lines patients to commercial meet you’re site metrics to time in just give that about talk sorts and of gauge thing soon Just of treatment launch, just early plan whether little the a you of first, to offering able those the dosed the we specified early what kind period, things. of color get of be Can the progress launch. and do approval help just investors

David. Thanks,

that over no appreciate, nascent a as disruptive a that you’ll options. I’ll and intervention to therapeutic somewhat hand this But question historically a Jason. space yes, therapeutic is So into market has

assess do the we to we have, to obviously, progress So be that cautious as have metrics the using Jason? to stages, how in very be we but will we track, early

question. the for Thanks

guys metrics tracking So you anticipate always going we’re launches, the a going and engaging demonstrate be care want we activity Typically, robust success. of that of in to launch. the team obviously, with stakeholder internally, are during track core launch activity metrics to to progress to know providers audiences different that multitude and the launch health I’m provide imperative and

In addition Every different. that, bit launch a bit is is little launch a unique. to every

the sure metrics while I in launch I’m so And the is today, why that the metrics that picture you can’t paint because disclose to are give early specific for we’ll going. the you phases specifically reason of going not which how of is launch

quantitative that the you a intent going picture with that both how launch and so over time. qualitative assess we’re how metrics doing you is can market of paint anticipated the to so my provide And in is

not metrics of picture and a your But what least launch how but those qualitative specific specifically I that’s provides at for today it that can’t is intent I are launch the how you with to quantitative of tell question, the we’re answer know paint you at progressing. demonstrating that progress. you

Yes.

Okay, question with driving payers. been I reimbursement see. that That’s helpful. a then I and have coverage on And guys the process. know you had I just front

part they Or Just efforts your the curious feel that co-promotion as something any payers? to scheme agreement? contribute as that own conversations prevention of support terms or your well in in that regard? market you lend to of in Is with and could kind of access is with can Sanofi whether just hand

Jason?

the David. Yes, question, absolutely, answer is the to

is that field-based team, values is agreement the access a the the of co-promotion and teams outcomes market team. of One part the

And will Sanofi access so partnering with and reimbursement on actively as be well. market we field-based

with Capital Gregory from Your Markets. next Renza question RBC comes

It’s Anish for Greg. [ph] on

the congrats quarter. on First of all,

for get are your wanted for take mind, teplizumab the macro/clinical the perspective, to prepandemic to in with UMB visits your what at-risk From screening Just you to this And landscape. expectations your do on to levels? when in-office return program? patient expect

take Thank do you you one? to question. the want Jason, for that

have I post-pandemic it’s great hearing recommenced question. think And field. in visits Yes, respect what great And think from it’s in-office patient screening, question. I we’re to a a with already the

are there can screened think multiple today. getting I different a ways that go patient about

$XX available mentioned autoantibody of we’ve commercial have Quest like through website X. out-of-pocket antibody associated an have database and previous their are out-of-pocket or during know panel patients XX% Quest. assays data an LabCorp’s an on LabCorp We or I’m auto of cost of XX% readily Labs with that labs available As through less in sorry, calls, and

only is there test is Detect are also their the supported program. not test options by So the JDRF and TX reimbursed at-home available,

are we JDRF physician we I less in their TX a patients nearly and global the part panel program see own table, in roll ago year. get well drug early anticipate can against as this kit conducted to have inclined kitchen think the visit from get in X was for go being this of order detect person that their to the years able But next pandemic, of launching patients from through an comfort timed. and really home potentially being to test out able screened of an to autoantibody their in-person the So physician a which comfort backdrop of

back remarks. this over gentlemen, our and like closing Palmer Ashleigh I for question-and-answer to would conference the turn question. Ladies any concludes to

day. the Thank of enjoy rest you, updated for We today. in forward to keeping you Please operator, all weeks. joining and your thank coming the look you

has The now today’s concluded. you joining Thank conference presentation. for

now may You disconnect.